Transcatheter atrial septal defect closure in an infant (body weight 6.4 kg) using the GORE CARDIOFORM septal occluder (GCSO)

Roman Scheidmann*, Thomas Paul and Matthias Sigler

Abstract

Introduction: Transcatheter closure has become the treatment of choice for secundum atrial septal defects (ASD II), but particularly in small children, there is concern regarding procedure-related complications.

Case description: We report on a 10-month-old infant, body weight of 6.4 kg, with a large ASD who was referred for failure to thrive and dyspnea on exertion. Echocardiography showed two neighboring ASDs centrally located within an atrial septum with a length of 27 mm resulting in significant left-to-right shunting. During cardiac catheterization, hemodynamic significance of the defect as well as normal pulmonary vascular resistance was demonstrated. Balloon sizing of the central ASD showed a stretched defect diameter of 12 × 11 mm. A 20-mm GORE CARDIOFORM septal occluder (GCSO; Goremedical, W. L. Gore & Associates, Inc., Newark, DE, USA) was implanted without any complications. Initial trivial residual shunting resolved during 4 months of follow-up. Right ventricular dimensions declined significantly, and the boy gained body weight properly.

Discussion, evaluation and conclusion: As demonstrated in our report, even large ASDs can be closed safely by catheter intervention in small infants. Selection of implant device and optimal sizing is of paramount importance. The size of the delivery sheath (11 French in our patient) is a potential limitation for the GCSO in smaller infants.

Keywords: Atrial septal defect of secundum type (ASD II), GORE CARDIOFORM septal occluder (GCSO), Transcatheter ASD closure, Interventional therapy, Endovascular procedure

Background

Transcatheter closure has become the treatment of choice for secundum atrial septal defects. A wide range of occlusion devices is available, but concern has been raised about procedure-related adverse events, especially cardiac erosion and vascular damage, with an increased risk in small patients [1].

Case description

We report the case of an infant with Down’s syndrome who underwent transcatheter ASD closure using the GORE CARDIOFORM septal occluder (GCSO) with 6.4 kg body weight. The boy had been referred due to failure to thrive and dyspnea on exertion.

Echocardiography showed two neighboring ASDs centrally located within the atrial septum with a length of 27 mm resulting in significant left-to-right shunting, significant right heart enlargement, and functional pulmonary stenosis.

Due to persistent failure to thrive at 10 months of age, the baby underwent cardiac catheterization under general anesthesia. Catheter intervention was guided by transoesophageal echocardiography and fluoroscopy (Fig. 1). Balloon sizing of the central ASD demonstrated a stretched defect diameter of 12 × 11 mm (Fig. 2). The smaller, craniodorsally located defect measured 4 × 2 mm. Hemodynamic evaluation confirmed significant left-to-right shunting (pulmonary flow/systemic flow (Qp/Qs) = 2.5:1).

Initially, it was decided to implant a 25-mm GCSO in order to cover both ASDs. The device was loaded into the sheath after careful flushing with normal saline. Before introducing, a guide wire had been placed into the
upper left pulmonary vein through an 11 French introducer sheath (Terumo Corp., Tokyo, Japan). The sheath with the loaded device was then forwarded using the monorail technique. After unfolding of the left atrial disc in the left atrium, the cranial edge of the disc was repetitively slipping through the defect into the right atrium due to the system’s intrinsic stiffness and an angle of 45° between the atrial septum plane and the application sheath. Therefore, it was decided to switch to a smaller 20-mm device albeit its potential risk of residual shunting. Device implantation was performed into the larger ASD without any complications but trivial residual shunting (Qp/Qs = 1.2:1) through the smaller ASD (residual defect size 2 × 1 mm) due to incomplete device coverage. Fluoroscopy time was 16 min.

The baby received periprocedural antibiotic therapy with cefazolin (100 mg/kg). For avoiding clot formation, unfractionated heparin (200 IE/kg) was given for the first 48 h followed by acetyl salicylic acid for 6 months.

No procedure-related complications were documented by follow-up routine diagnostic examinations (electrocardiogram, transthoracic echocardiography and duplexsonography of femoral veins), particularly no electrocardiographic alterations, cardiac erosion, pericardial effusion, or vascular damage at the access site. Correct position of the device and initial residual shunting was documented by routine transthoracic echocardiography. Within the following weeks, right ventricular dimensions diminished significantly. The boy thrived properly. Four months after interventional closure, no residual shunt was detectable by transthoracic echocardiography.

**Discussion and evaluation**

As demonstrated in our report, large ASDs can be closed safely by catheter intervention even in small
infants. Bishnoi et al. analyzed technical aspects and complications related to interventional ASD closure in 68 infants < 8 kg from 10 different hospitals in the USA. Data suggest that interventional ASD closure was safe and effective, resulting in significant clinical improvement [2]. Data from Wyss et al. and Abu-Tair et al. support these findings reporting 14 and 28 infants with a body weight < 10 kg respectively who underwent interventional ASD closure without any major complications [3, 4].

Selection of type and optimal size of the device may sometimes be challenging. In the face of the small size of the baby and potential mechanical tissue trauma, the use of the GCSO was favored due to its more soft and flexible design compared to metal–mesh-based occlusion devices such as the Amplatzer Septal Occluder (Abbot, St. Paul, MN). As demonstrated in our report, it might be necessary to switch to a different device size in order to safely position the implant in the defect.

Furthermore, over- and undersizing should be avoided whenever possible since inappropriate size of the occlusion device was identified as a main risk factor for cardiac erosion and perforation respectively [5].

Even if complete closure of the defect cannot be achieved initially, the clinical status is often improved by reducing shunt volume to a hemodynamically insignificant level. Small ASDs, as in our patient, have a high rate of spontaneous closure [6].

**Conclusion**

The size of the introducer sheath (11 French in our patient) is probably the main limiting factor for the GCSO in infants. This problem can be addressed by a new delivery technique where the delivery sheath serves as the introducer so that vascular access size requirement can be reduced by 25% [7]. In our case, we decided to use the GCSO because of its more soft and flexible design compared to the Amplatzer septal occluder, as mentioned above. We wanted to primarily reduce any risk of potential cardiac trauma by the device. This aspect was given priority over a possible vascular damage by a large introducer system.

On the other hand, the definite risks and inherent complications of open-heart surgery under cardiopulmonary bypass can be avoided by using an interventional approach in the therapy of a hemodynamically significant ASD [8].

**Abbreviations**

ASD: Atrial septal defect; GCSO: GORE CARDIOFORM septal occluder; Qp/Qs: Qp = Pulmonary flow. Qs = Systemic flow. The ratio Qp/Qs describes the magnitude of a cardiovascular shunt

**Acknowledgements**

Not applicable.

**Availability of data and materials**

Data can be found in the archives of the Department of Pediatric Cardiology and Intensive Care Medicine, Georg-August-University, Robert-Koch-Str. 40, D-37075, Göttingen, Germany.

**Authors’ contributions**

All authors contributed equally to the preparation and writing of the case report. The intervention had been performed by M. S. All authors read and approved the final manuscript.

**Funding**

No funding was received for this research project.

**Ethics approval and consent to participate**

Not applicable.
Consent for publication
Written informed consent was obtained from the parents of the patient.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 10 August 2017 Accepted: 27 October 2017
Published online: 03 November 2017

References
1. Backes CH, Cua C, Kreutzer J, Armsby L, El-Said H, Moore JW, Gauvreau K, Bergersen L, Holzer RJ (2013) Low weight as an independent risk factor for adverse events during cardiac catheterization of infants. Catheter Cardiovasc Interv 82:786–794

2. Bishnoi RN, Everett AD, Ringel RE, Owada CY, Holzer RJ, Chisolm JL, Radtke WA, Scott Lim D, Rhodes JF Jr, Coulson JD (2014) Device closure of secundum atrial septal defects in infants weighing less than 8 kg. Pediatr Cardiol 35:1124–1131

3. Wyss Y, Quandt D, Weber R, Stiasny B, Weber B, Kirschnich W, Kretschmar O (2016) Interventional closure of secundum type atrial septal defects in infants less than 10 kilograms: indications and procedural outcome. J Interv Cardiol 29:646–653

4. Abu-Tair T, Wihlroh CM, Kehr J, Kuroczyński W, Kampmann C (2016) Transcatheter closure of atrial septal defects using the Gore® septal occluder in children less than 10 kg of body weight. Pediatr Cardiol 37:778–783

5. Thomson JDR, Qureshi SA (2015) Device closure of secundum atrial septal defect’s and the risk of cardiac erosion. Echo Res Pract 2:R73–R78

6. Garne E (2006) Atrial and ventricular septal defects—epidemiology and spontaneous closure. J Matern Fetal Neonatal Med 19:271–276

7. Anderson JH, Fraint H, Moore P, Caballero AK, Taggart NW (2017) Novel delivery technique for atrial septal defect closure in young children utilizing the Gore® CARDIOFORM(R) septal occluder. Catheter Cardiovasc Interv 89:1232–1238

8. Ooi YK, Kelleman M, Ehrlich A, Glanville M, Porter A, Kim D, Kogon B, Oster ME (2016) Transcatheter versus surgical closure of atrial septal defects in children: a value comparison. JACC Cardiovasc Interv 9:79–86

Submit your manuscript to a SpringerOpen journal and benefit from:

- Convenient online submission
- Rigorous peer review
- Open access: articles freely available online
- High visibility within the field
- Retaining the copyright to your article

Submit your next manuscript at

SpringerOpen.com